Dyadic International (NASDAQ:DYAI) Announces Earnings Results, Misses Estimates By $0.03 EPS

Dyadic International (NASDAQ:DYAI) released its quarterly earnings results on Wednesday. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.03), FiscalAI reports. The company had revenue of $0.57 million during the quarter, compared to the consensus estimate of $1.34 million. Dyadic International had a negative net margin of 221.09% and a negative return on equity of 537.31%.

Dyadic International Price Performance

NASDAQ DYAI traded up $0.03 on Wednesday, hitting $0.87. 100,893 shares of the company’s stock were exchanged, compared to its average volume of 60,286. The stock has a 50-day moving average of $0.83 and a 200-day moving average of $0.95. The stock has a market cap of $31.58 million, a price-to-earnings ratio of -3.64 and a beta of 1.29. Dyadic International has a 52 week low of $0.71 and a 52 week high of $1.45. The company has a current ratio of 2.85, a quick ratio of 2.85 and a debt-to-equity ratio of 1.92.

Institutional Trading of Dyadic International

Several institutional investors and hedge funds have recently modified their holdings of DYAI. Landscape Capital Management L.L.C. bought a new position in Dyadic International in the 3rd quarter valued at approximately $190,000. Geode Capital Management LLC increased its position in Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 36,266 shares during the period. Finally, Bank of America Corp DE increased its position in Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares during the period. 27.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Dyadic International currently has an average rating of “Hold” and an average price target of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.